The Rationality to Use of Galectin-3 as Target in Biomarker-Guided Therapy of Type 2 Diabetes Mellitus
| dc.contributor.author | Berezin, A. E. | |
| dc.contributor.author | Березін, Олександр Євгенійович | |
| dc.date.accessioned | 2016-06-14T12:36:45Z | |
| dc.date.available | 2016-06-14T12:36:45Z | |
| dc.date.issued | 2016 | |
| dc.description.abstract | Galectin-3 is a multifunctional chimaera-type β-galactoside binding protein that has been linked to incident Cardiovascular (CV) and renal disease, fibrosis and tissue injury. Elevated level of serum galectin-3 was found in patients with Type 2 Diabetes Mellitus (T2DM) and associate well with CV complications. The short commentary depicts the role of galectin-3 in risk stratification in T2DM individuals. Although perspectives of clinical implementation of galectin-3-guided therapy in T2DM patients are widely discussed, there is evidence regarding cyto-protective role of galectin-3 in diabetes. Whether is rationale to achieve full control under serum galectin-3 as a predictor of successful T2DM treatment is not clear. Further investigations are needed to explain the role of galectin-3 in T2DM development and progression. | uk_UK |
| dc.identifier.citation | Berezin A. The Rationality to Use of Galectin-3 as Target in Biomarker-Guided Therapy of Type 2 Diabetes Mellitus [Electronic resource] / A. Berezin // Endocrinology & Metabolic Syndrome. – 2016. – Vol. 5, № 1. – p. 3. | uk_UK |
| dc.identifier.uri | https://zsmu.rosbai.com/handle/123456789/3727 | |
| dc.language.iso | en | uk_UK |
| dc.subject | Diabetes mellitus | uk_UK |
| dc.subject | Biomarkers | uk_UK |
| dc.subject | Galectin-3 | uk_UK |
| dc.subject | Risk stratification | uk_UK |
| dc.subject | Targeting for therapy | uk_UK |
| dc.title | The Rationality to Use of Galectin-3 as Target in Biomarker-Guided Therapy of Type 2 Diabetes Mellitus | uk_UK |
| dc.type | Article | uk_UK |